Since the establishment of Shenzhou Cell Engineering Co., Ltd. under the Group in 2002, the company has long adhered to independent research and development and self -master core technologies, has established a full set of technology platforms for biopharmaceuticals and vaccines, and independently developed a competitive rich product pipeline, covering coverage Malignant tumors, autoimmune diseases, genetic diseases, and disease prevention. In July 2021, the company lasted for 14 years. The first domestic reorganized coagulation products (Anjiayin®), which was treated with rare diseased hyperactivity disease treatment, realized listing and sales. At the end of August 2022, the company's first antibody drug and the first anti -tumor product Ripupozab (Anpingxi®) was approved to be listed. In December 2022, in March 2023, the company's independently developed reorganized new crown virus (Alpha/Beta mutant strain) S SCTV01C (Anno Neng® 2) and its iterative product reorganization of new crown virus 4 prices ( Alpha/Beta/Delta/Omicron) S trimer protein vaccine SCTV01E (Anno ®4) has been incorporated into the country into emergency use.
The company's management team has rich experience in research and development and production of biopharmaceuticals. Dr. Xie Liangzhi, the founder of the company, was a doctorate in MIT at the Massachusetts Institute of Technology, and successfully tried the animal cell flow plus cultivation technology controlled by complex, variables and associated chemical measurement methods. In 1994 By the leading level of 2,400 mg/liter, it laid an important foundation for the large -scale production of antibody drugs; after returning to China in 2002, it assumed a number of national "863" plans, and the national "new drug creation" major topic topics; led the team to establish the international international The first-class biopharmaceutical research and development and industrialization technology platform has broken through a series of key technologies, overcome high-difficult biopharmaceutical production technology such as reorganized coagulation, long-term interferon-β, and 14-valent HPV vaccine; the company's deputy general manager Wang Yang Doctors have more than 20 years of experience in the research and development and project management of vaccines and antibody drugs. They have led the quality analysis and quality standards of cervical cancer vaccine. They are internationally renowned biopharmaceutical control experts.
The company's production bases located at the Beijing Economic and Technological Development Zone Headquarters are all constructed in accordance with the CGMP standard. Among them, the first phase of the project has been built in the 12,000 -liter original liquid production line that can realize commercial production; The remaining two raw liquid production lines of the same scale are under construction. The company obtained the "Drug Production License" in July 2018, and the new vaccine production license was added at the end of May 2022.
The company first publicly issued shares on June 22, 2020 and was listed on the Shanghai Stock Exchange Science and Technology Board.